ATZ.TO 1.94NOW -3.18NVDA 3.13PPL.TO 1.01ARE.TO 2.35ENR.DE-XETRA 0XLK 1.95XMU.TO 0.295
Abbott Labs (ABT)

NYSE:ABT

Abbott Labs (ABT)

97.34
+0.65 (0.67%)
as of Oct 2, 2026, 6:46:12 pm Market Open.
354 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
TOP PICK

Abbott Labs(ABT)

Apr 26, 2010
Pharma company. Nutritional division. Adult’s nutrition. Likes the diversification. Consistently increases dividend, about 3-1/2% at present. Recently beat numbers. Pulled earning back by 7%, but it is manageable.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$50.37

Stock price when the opinion was issued

$97.50

As of Oct 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Apr 14, 2010
Great company with a great pipeline. Humira, a rheumatoid arthritis drug, is their major product is on patent until 2016. Have never had a down year in stock price since 1992.
Photo of Don LatoDon Lato
Owned
Unlock Rating
$52.31

Stock price when the opinion was issued

$97.50

As of Oct 02, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Abbott Labs(ABT)

Jan 14, 2010
Not hot on pharmaceuticals because of generic manufacturing and litigation risks. This one is a pretty good choice in pharmaceuticals with a pretty good product line up going forward. A lower risk way to play pharmaceuticals is through Johnson & Johnson (JNJ-N) that has both pharmaceuticals and branded consumer products.
Photo of David BaskinDavid BaskinUnlock Rating
$55.35

Stock price when the opinion was issued

$97.50

As of Oct 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Jan 13, 2010
Trading at about 13X earnings. Expects revenues to grow at 8%-10% and earnings to grow 12%-14%. 2.9% dividend. 7.5% free cash flow.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$55.29

Stock price when the opinion was issued

$97.50

As of Oct 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Jul 08, 2009
Medical company, pharma and diagnostics. Good solid holding. Pays a good dividend. Good core holding for a portfolio.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$46.31

Stock price when the opinion was issued

$97.50

As of Oct 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Nov 21, 2008
Diagnostic equipment stents and some new blockbuster drugs. Drug industry and healthcare services might come under some pressure with the new administration, which is the risk they may face.
Photo of Walter GerasimowiczWalter Gerasimowicz
Owned
Unlock Rating
$51.52

Stock price when the opinion was issued

$97.50

As of Oct 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Aug 29, 2007
In the healthcare area this is an attractive name. Have medical devices, nutrition products and pharmaceuticals. Had troubles a few years ago but has gotten its act together.
Photo of Norman LevineNorman LevineUnlock Rating
$51.49

Stock price when the opinion was issued

$97.50

As of Oct 02, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Abbott Labs(ABT)

Aug 25, 2005
Pharmaceuticals is a group that has underperformed for about 3 years. This one, in relation to the rest of the group, has peformed better althoough all of them are retracing over the last couple of months. Prefers the bioceutical companies.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$45.11

Stock price when the opinion was issued

$97.50

As of Oct 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

May 21, 2004
Has paid a dividend for 80 years. Trades at a discount to the market multiple but has new drug pipeline coming on. As simple, safe story.
Photo of Harvey EisenHarvey Eisen
Owned
Unlock Rating
$40.00

Stock price when the opinion was issued

$97.50

As of Oct 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Apr 30, 2004
Attractive. Continuing turnaround in their diagnostic business as well as a better pipeline than some of the other chief pharmaceuticals.
Photo of David KingDavid KingUnlock Rating
$44.02

Stock price when the opinion was issued

$97.50

As of Oct 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Sep 03, 2003
Spinning off their hospital products division. A good strategy as there is not much growth. Not too expensive.
Photo of Brad WillockBrad WillockUnlock Rating
$41.75

Stock price when the opinion was issued

$97.50

As of Oct 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Dec 10, 2001
Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
Photo of David BurrowsDavid BurrowsUnlock Rating
$55.50

Stock price when the opinion was issued

$97.50

As of Oct 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Jan 08, 2001
Getting into acquisitions. Had to restructure. Moving from a value to a growth stock
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$42.56

Stock price when the opinion was issued

$97.50

As of Oct 02, 2026. Market Open.

biotechnologypharmaceutical
Showing 211 to 223 of 223 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

BSX -0.56$42.67
NVO -0.06$37.34
ATD.TO -0.3$76.9
TOU.TO 1.33$61.99
HPS.A.TO 6.87$295.6

Today's Top Picks

ATZ.TO 1.94$122.66
NOW -3.18$134.58
NVDA 3.13$233.99
PPL.TO 1.01$65.46
ARE.TO 2.35$59.17

Popular Articles

Latest Sell Signals

LULU -1.58$94.28
BCE.TO -0.18$28.17
POET 0.21$7.85
NKE -1.27$33.88
RH 0.235$120.745

Most Recent Experts

Bruce Murray

Bruce Murray

The Murray Wealth Group

Dennis Mitchell, CFA

Dennis Mitchell, CFA

Sentry Select Capital Corp

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like